United Therapeutics Corporation (UTHR) Spending and interest coverage
- R&D / revenue · 12 months: Value 17.48%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 4.93%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 17.48% | Research and development expense / revenue. Period ending 2026-06-30. $551.50M ÷ $3.15B × 100 ≈ 17.48% |
| Stock-based compensation / revenue · 12 months | 4.93% | Share-based compensation / revenue. Period ending 2026-06-30. $155.40M ÷ $3.15B × 100 ≈ 4.93% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 551.50M USD | Research and Development Expense |
| Revenue | 3.15B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 155.40M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.40B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $551.50M | $3.15B | $155.40M | $1.40B | (m) | 17.48% | 4.93% | (m) | (m) |
| 2026-03-31 | $539.20M | $3.17B | $149.80M | $1.44B | (m) | 17.01% | 4.73% | (m) | (m) |
| 2025-12-31 | $550.00M | $3.18B | $147.70M | $1.49B | (m) | 17.28% | 4.64% | (m) | (m) |
| 2025-09-30 | $544.30M | $3.13B | $135.70M | $1.49B | (m) | 17.40% | 4.34% | (m) | (m) |
| 2025-06-30 | $520.30M | $3.08B | $138.30M | $1.45B | (m) | 16.90% | 4.49% | (m) | (m) |
| 2025-03-31 | $525.90M | $2.99B | $150.20M | $1.40B | (m) | 17.56% | 5.02% | (m) | (m) |
| 2024-12-31 | $481.00M | $2.88B | $144.00M | $1.38B | (m) | 16.72% | 5.00% | (m) | (m) |
| 2024-09-30 | $498.60M | $2.76B | $133.60M | $1.28B | (m) | 18.09% | 4.85% | (m) | (m) |
| 2024-06-30 | $479.80M | $2.62B | $113.00M | $1.26B | (m) | 18.34% | 4.32% | (m) | (m) |
| 2024-03-31 | $429.20M | $2.50B | $77.10M | $1.26B | $58.80M | 17.18% | 3.09% | 21.37× | Reported |
| 2023-12-31 | $408.00M | $2.33B | $39.10M | $1.18B | $59.30M | 17.53% | 1.68% | 19.98× | Reported |
| 2023-09-30 | $350.50M | $2.20B | $87.30M | $1.10B | $56.50M | 15.90% | 3.96% | 19.48× | Reported |
| 2023-06-30 | $331.90M | $2.11B | $63.80M | $1.09B | $50.10M | 15.72% | 3.02% | 21.71× | Reported |
| 2023-03-31 | $336.80M | $1.98B | $115.50M | $976.10M | $41.50M | 17.00% | 5.83% | 23.52× | Reported |
| 2022-12-31 | $322.90M | $1.94B | $106.80M | $979.70M | $32.40M | 16.68% | 5.52% | 30.24× | Reported |
| 2022-09-30 | $311.90M | $1.86B | $86.70M | $973.90M | $24.80M | 16.77% | 4.66% | 39.27× | Reported |
| 2022-06-30 | $325.00M | $1.79B | $113.70M | $888.30M | $20.20M | 18.17% | 6.36% | 43.98× | Reported |
| 2022-03-31 | $305.40M | $1.77B | $77.30M | $908.70M | $18.70M | 17.27% | 4.37% | 48.59× | Reported |
| 2021-12-31 | $540.10M | $1.69B | $138.50M | $555.90M | $18.60M | 32.04% | 8.22% | 29.89× | Reported |
| 2021-09-30 | $583.30M | $1.66B | $187.50M | $451.40M | $18.70M | 35.24% | 11.33% | 24.14× | Reported |
| 2021-06-30 | $572.80M | $1.59B | $150.40M | $443.80M | $19.00M | 36.01% | 9.46% | 23.36× | Reported |
| 2021-03-31 | $588.20M | $1.51B | $173.10M | $362.10M | $19.90M | 39.05% | 11.49% | 18.20× | Reported |
| 2020-12-31 | $357.70M | $1.48B | $163.80M | $593.60M | $23.50M | 24.12% | 11.04% | 25.26× | Reported |
| 2020-09-30 | $345.20M | $1.41B | $99.60M | $591.80M | $28.70M | 24.49% | 7.07% | 20.62× | Reported |
| 2020-06-30 | $362.20M | $1.43B | $136.00M | $554.10M | $35.50M | 25.31% | 9.50% | 15.61× | Reported |
| 2020-03-31 | $358.40M | $1.44B | $47.00M | $635.00M | $42.10M | 24.85% | 3.26% | 15.08× | Reported |
| 2019-12-31 | $1.18B | $1.45B | $45.40M | $-187.60M | $44.20M | 81.63% | 3.13% | -4.24× | Reported |
| 2019-09-30 | $1.21B | $1.52B | $18.70M | $-119.60M | $38.50M | 79.51% | 1.23% | -3.11× | Reported |
| 2019-06-30 | $1.22B | $1.53B | $46.20M | $-153.40M | $30.90M | 79.93% | 3.02% | -4.96× | Reported |
| 2019-03-31 | $1.22B | $1.60B | $103.90M | $-157.40M | $21.60M | 76.17% | 6.49% | -7.29× | Reported |
| 2018-12-31 | $357.90M | $1.63B | $-26.40M | $805.40M | $13.90M | 21.99% | -1.62% | 57.94× | Reported |
| 2018-09-30 | (m) | $1.71B | $89.30M | $812.90M | $13.10M | (m) | 5.22% | 62.05× | Reported |
| 2018-06-30 | (m) | $1.74B | $13.90M | $987.10M | $12.30M | (m) | 0.80% | 80.25× | Reported |
| 2018-03-31 | (m) | $1.74B | $-8.50M | $858.20M | $10.80M | (m) | -0.49% | 79.46× | Reported |
| 2017-12-31 | $264.60M | $1.73B | $73.50M | $814.90M | $9.00M | 15.34% | 4.26% | 90.54× | Reported |
| 2017-09-30 | (m) | $1.67B | $60.30M | $850.10M | $7.70M | (m) | 3.61% | 110.40× | Reported |
| 2017-06-30 | (m) | $1.63B | $134.20M | $764.90M | $4.90M | (m) | 8.22% | 156.10× | Reported |
| 2017-03-31 | (m) | $1.60B | $137.60M | $961.60M | $4.10M | (m) | 8.60% | 234.54× | Reported |
| 2016-12-31 | $147.60M | $1.60B | $12.10M | $1.06B | $3.90M | 9.23% | 0.76% | 272.23× | Reported |
| 2016-09-30 | $156.60M | $1.59B | $24.15M | $1.04B | $2.23M | 9.82% | 1.51% | 466.45× | Reported |
| 2016-06-30 | (m) | $1.57B | $-144.65M | $1.19B | $2.54M | (m) | -9.20% | 469.79× | Reported |
| 2016-03-31 | (m) | $1.51B | $-98.85M | $1.08B | $3.23M | (m) | -6.56% | 333.08× | Reported |
| 2015-12-31 | $245.10M | $1.47B | $280.25M | $699.01M | $4.74M | 16.72% | 19.12% | 147.63× | Reported |
| 2015-09-30 | $240.63M | $1.41B | $195.21M | $722.53M | $7.72M | 17.10% | 13.87% | 93.64× | Reported |
| 2015-06-30 | $349.98M | $1.35B | $534.46M | $303.22M | $11.59M | 25.91% | 39.56% | 26.16× | Reported |
| 2015-03-31 | $340.31M | $1.33B | $485.31M | $307.83M | $15.04M | 25.65% | 36.58% | 20.47× | Reported |
| 2014-12-31 | $242.55M | $1.29B | $190.05M | $538.80M | $17.59M | 18.82% | 14.75% | 30.63× | Reported |
| 2014-09-30 | $292.62M | $1.23B | $335.93M | $331.73M | $18.63M | 23.77% | 27.29% | 17.81× | Reported |
| 2014-06-30 | $246.49M | $1.20B | $189.99M | $468.62M | $18.46M | 20.48% | 15.79% | 25.39× | Reported |
| 2014-03-31 | $261.37M | $1.16B | $224.85M | $414.60M | $18.23M | 22.51% | 19.36% | 22.74× | Reported |
| 2013-12-31 | $299.35M | $1.12B | $320.79M | $292.50M | $18.06M | 26.80% | 28.72% | 16.20× | Reported |
| 2013-09-30 | $215.27M | $1.07B | $132.13M | $449.59M | $17.99M | 20.09% | 12.33% | 25.00× | Reported |
| 2013-06-30 | $207.68M | $1.01B | $88.89M | $425.66M | $17.83M | 20.52% | 8.78% | 23.87× | Reported |
| 2013-03-31 | $190.16M | $957.00M | $65.35M | $408.95M | $17.19M | 19.87% | 6.83% | 23.79× | Reported |
| 2012-12-31 | $173.39M | $916.08M | $30.11M | $421.65M | $16.64M | 18.93% | 3.29% | 25.34× | Reported |
| 2012-09-30 | $184.55M | $867.44M | $62.64M | $356.55M | $17.26M | 21.27% | 7.22% | 20.66× | Reported |
| 2012-06-30 | $178.82M | $826.71M | $-16.11M | $378.81M | $18.29M | 21.63% | -1.95% | 20.71× | Reported |
| 2012-03-31 | $165.97M | $784.88M | $-52.59M | $387.72M | $19.84M | 21.15% | -6.70% | 19.54× | Reported |
| 2011-12-31 | $180.01M | $743.18M | $-15.71M | $317.78M | $21.37M | 24.22% | -2.11% | 14.87× | Reported |
| 2011-09-30 | $194.75M | $722.63M | $15.03M | $262.30M | $21.71M | 26.95% | 2.08% | 12.08× | Reported |
| 2011-06-30 | $175.65M | $689.46M | $94.01M | $221.81M | $21.11M | 25.48% | 13.63% | 10.51× | Reported |
| 2011-03-31 | $179.92M | $640.57M | $120.67M | $168.64M | $20.44M | 28.09% | 18.84% | 8.25× | Reported |
| 2010-12-31 | $166.76M | $603.83M | $113.94M | $164.00M | $19.71M | 27.62% | 18.87% | 8.32× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $122.19M | $369.85M | $101.02M | $26.00M | $12.88M | 33.04% | 27.31% | 2.02× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $239.18M | $281.50M | $28.70M | $-82.06M | $11.44M | 84.97% | 10.20% | -7.17× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |